Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarceva plus Temodar and Radiation in Newly Diagnosed Glioblastoma
NCT00187486Phase 2Completed
- Sponsor
- University of California, San Francisco
- Start
- Aug 2004
- Primary completion
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib in glioblastoma multiforme (GBM), Gliosarcoma (GS), sponsored by University of California, San Francisco. Started Aug 2004; status: completed.
02
Drugs
erlotinib
03
Conditions
glioblastoma multiforme (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT00187486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00187486.